Antidiabetic and Hypolipidaemic Effects of Citrus aurantifolin Leaves on Hyperglycaemic and diabetic Rats by Howeida, Mustafa A. et al.
 1 
Paper 3 
Antidiabetic and Hypolipidaemic Effects of Citrus aurantifolin Leaves on 
Hyperglycaemic and diabetic Rats 
Mustafa A. Howeida 
1
, Eltayeb B. Idris 
2
, Ali M. Almahdi 
3
, Shaddad A. Sania
4
 
Mohammad H. Abdelwahhab
5
 
1 
Ahfad University, School of Medicine, Department of Biochemistry and 
Pharmacology 
2
 University of Khartoum, Faculty of Pharmacy. Department of Pharmacology. 
3
 University of Khartoum. Faculty of Medicine. Department of Internal Medicine. 
4 
University of Khartoum. Faculty of Pharmacy. Department of Pharmacology. 
5
 National Centre for Researches, Medicinal and Aromatic Plants` Research Institute 
(MAPRI). Department of Pharmacology. 
 
Abstract 
Objectives: This research aimed to study the hypoglycaemic and 
hypolipidaemic effects of aqueous and methanolic extracts of Citrus aurantifolin 
leaves, in hyperglycaemic (type II)  and Streptozotocin diabetic rats (type I). 
Methodology:  This plant was phytochemically screened using the standard 
methods for determination of its chemical composition., The hypolipidaemic  and 
hypoglycaemic effects were determined following the Glucose tolerance test (GTT) 
model and the results were compared to the control and the reference drugs Insulin 
and Glibenclamide for types I and II diabetes mellitus respectively.  
Results: Phytochemical screening of C.aurantifolin revealed presence of 
sterols (++), alkaloids (+), fla64rfc 64rfc 4wsazThe results of this research in type II 
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showed  that both extracts of C.aurantifolin  exhibited an early persistent 
hypoglycaemic effect in type II hyperglycaemic rats as compared to the control.  Both 
doses of the aqueous extract and dose 400 mg ∕ kg of the methanolic extract reduced 
blood glucose significantly (P <0.001) throughout the experiment, while dose 200 mg 
∕ kg of the methanolic extract reduced blood glucose  significantly  (P<0.05) 
throughout the experiment. In type I diabetic rats, the hypoglycaemic effect was slow 
but highly significant (P <0.001) as it only started at the 4
th
 hour post dosing. 
Regarding the effect of C.aurantifolin on blood cholesterol, the aqueous extract  
showed an earlier, less persistent and highly significant (P <0.001)  
hypocholesterolaemic effect in type II hyperglycaemic rats than the methanolic 
extract as its effect occured at the 1
st
 hour only while dose 400 mg/kg  of the 
methanolic reduced cholesterol level significantly (P<0.05), at the 2
nd
 and 4
th
 hours 
and dose 200 mg/kg at the 1
st
 and 2
nd
 hours post dosing. In type I diabetic rats, dose 
400 mg/kg and Insulin,showed a significant (P <0.05) hypocholesterlaemic  effect at 
the 4
th
 hour post dosing, the effect of the extract continued to the 8
th
 hour. The highest 
significant reduction (P <0.001)  was exhibited by dose 200mg/kg of the methanolic 
extract at the 4
th
 hour post dosing. Concerning blood triglycerides, both the aqueous 
and methanolic extracts of C.aurantifolin,  reduced blood triglycerides significantly (P 
<0.001) and (P<0.05),at the 2
nd
 and 4
th
 hours post dosing, respectivly.In Type I 
diabetic rats,the effect of the aqueous extract  was  highly significant  (P <0.001) since 
the 1
st
 hour  and continued throughout the experiment. The methanolic extract, 
reduced blood triglycerides significantly  (P<0.05)  8 and 12 hours post  dosing while 
the effect of Insulin was significant    (P<0.05)    since the 1
st
 hour and continued 
throughout the experiment.                                                                                  
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In conclusion the leaves of C.aurantifolin confirmed its traditional use in herbal 
medicine as a hypoglycaemic and hypolipidaemic agent which can be very effective. 
Introduction 
Diabetes is world-wide in distribution and its incidence is rising. In the year 
2000, 150 million people world-wide had diabetes, and this is expected to double by 
2010 
(1)
. In spite of the introduction of synthetic hypoglycaemic agents, diabetes and 
the related complications continue to be a major medical problem 
(2)
.Therefore the 
search for more effective and safer hypoglycaemic agents has continued to be an 
important area of active research 
(3)
. Many medicinal plants have been found to be 
successful in management of diabetes 
(4)
. However, search for new antidiabetic drugs 
continue.  
Citrus aurantifolin (Family Rutaceae) is  a spine scent tree up to 6 m in 
height. Its cultivated in various areas of the world. It contains volatile 
oils,terpeins,hesperidin and vitamin B,citric acid,vitamin C, potassium and calcium 
citrate and flavinoides. In folk medicine,the stem is used  as an antiseptic for mouth, 
the juice is used for treatment of rhinitis and cold and can be added to coffee and tea 
for abdominal pain
(5)
. 
Materials and Methods 
Plants 
The leaves of Citrus aurantifolin are brought from a home garden in Omdurman city. 
Preparation of the aqueous extract 
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50 grams of the leaves of C.aurantifolin were weighed, immersed in cooled boiling 
distilled water and then incubated in a water bath at 60
°
c
 
for four hours after which 
they were filtered. The filtrate was freeze dried 
(6)
. 
Preparation of the methanolic extract  
60 grams of the bark of C. aurantifolin were weighed and packed in Soxhlet apparatus 
using 500 ml of petroleum ether followed by chloroform, as solvents to separate lipids 
and terpenoids. The sample was then extracted using methanol as a solvent to get the 
polar constituents of the plants. The extract was evaporated till dryness using a 
rotatory evaporator 
(6)
.
 
 
Animals 
Adult male Wistar albino rats weighing 70-300 grams were used in this study. Rats 
were obtained from the Faculty of Pharmacy, University of Khartoum. They were 
divided into groups of tens among the controls, standards and subgroups of samples. 
They were supplied with a standard pellet diet and tap water ad libitum. 
Experimental type II diabetes mellitus: 
(Glucose tolerance test) 
Rats were divided into groups of tens among the controls, standards and samples. 
After eighteen hours - fast, blood samples were obtained from the retro orbital plexus 
of rats 
(7)
, using heparinized capillary tubes. The (0) time sample was collected and 
then all groups of animals were over- loaded with (2g/kg) of 50% glucose 
intraperitoneally; the control was given distilled water, the standard was given (10 
mg/kg) of Glibenclamide while the tested groups were given (400 and 200 mg /kg) of 
the aqueous and methanolic extracts orally. The 1, 2 and 4 hours samples, were 
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collected and the plasma obtained after centrifugation was estimated for glucose, 
cholesterol and triglycerides. 
Experimental type I diabetes mellitus: 
 (Streptozotocin – induced diabetes)  
In this experiment, induction of diabetes in rats was achieved by destruction of the 
pancreatic cells using   an intraperitoneal  injection of Streptozotocin (STZ), at a dose 
of (60 mg / kg b wt), dissolved in citrate buffer at a concentration of (20 mg / ml) to 
provide a pH of 4.5 
(8)
 and 
(9)
. Soluble insulin at a dose of (3U/kg diluted 100 times) 
was used as standard (reference drug) and samples were collected at 0, 4, 8 and 12 
hours 
(10)
 Samples were then analysed biochemically for glucose 
(11)
 cholesterol 
(12)
 
and triglycerides 
(13)
.
 
  
Statistical analysis 
Data were expressed as means ± standard error of means using paired student’s t – 
test 
(14)
. 
Results 
Phytochemical screening revealed presence of triterpenes alkaloids, tannins and 
saponin (Table 1).  
  Both doses of the aqueous extract and dose 400 mg ∕ kg of the methanolic extract 
reduced blood glucose significantly (P <0.001) throughout the experiment, while dose 
200 mg ∕ kg of the methanolic extract reduced blood glucose  significantly  (P<0.05) 
throughout the experiment. In type I diabetic rats, the hypoglycaemic effect  of both 
extraxts was slow but highly significant (P <0.001) as it only started at the 4
th
 hour 
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post dosing. Regarding the effect of C.aurantifolin on blood cholesterol, the aqueous 
extract  showed a significant (P <0.001)  hypocholesterolaemic effect at the 1
st
 hour  
in type II hyperglycaemic rats. The effect of the methanolic extract occured at the 1
st
 
hour only while dose 400 mg/kg  of the methanolic reduced cholesterol level 
significantly (P<0.05), at the 2
nd
 and 4
th
 hours and dose 200 mg/kg at the 1
st
 and 2
nd
 
hours post dosing. In type I diabetic rats, dose 400 mg/kg and Insulin,showed a 
significant (P <0.05) hypocholesterlaemic  effect at the 4
th
 hour post dosing, the effect 
of the extract continued to the 8
th
 hour. The highest significant reduction (P <0.001)  
was exhibited by dose 200mg/kg of the methanolic extract at the 4
th
 hour post dosing. 
Concerning blood triglycerides, both the aqueous and methanolic extracts of 
C.aurantifolin,  reduced blood triglycerides significantly (P <0.001) and (P<0.05),at 
the 2
nd
 and 4
th
 hours post dosing, respectivly.In Type I diabetic rats, the effect of the 
aqueous extract  was  highly significant  (P <0.001) since the 1
st
 hour  and continued 
throughout the experiment. The methanolic extract, reduced blood triglycerides 
significantly (P<0.05) 8 and 12 hours post dosing while the effect of Insulin was 
significant    (P<0.05)    since the 1
st
 hour and continued throughout the experiment.  
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Table 1 
 General Phytochemical screening of Citrus aurantifolin leaves,  
Chemical Ingredient Citrus aurantifolin 
Sterols  ++ 
Triterpenes - 
Alkaloids + 
Flavonoides + 
Tannins + 
Anthraquinones - 
Saponin + 
Cyanogenic glycosides + 
Coumarins + 
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Table 2 
Effects of the aqueous extract of C.aurantifolin on the blood glucose, cholesterol and 
triglycerides of hyperglycaemic rats: 
 
Name of Group 
Blood Glucose (mg/dl) 
Time (hours) 
 0 1 2 4 
Control (water) 110±8.9 166.8±7.51 129.4±17 110.4±8.5 
Glibenclamide (10 mg/k 105±5.8 
 
141.7±32.8 
 
87.38±2.89 
 
86.7±10.45* 
C.aurantifolin (400 
mg/kg 
90±10.6 
 
149.5±9.1* 
 
76±10.5** 
 
75.9±6.9** 
 
C.aurantifolin 
(200mg/kg) 
87.8±2.7 
 
127±11.3*. 
 
87.2±4.8** 
 
100.9±0.73** 
 
Cholesterol (mg/dl) 
Control (water) 75.8±6.7 
 
104.2±16.8 
 
107.2±6.4 
 
83.5±6.4 
 
Glibenclamide (10 
mg/kg) 
88±8.87 
 
87±8.2 
 
83.6±2.8* 
 
86.4±21.2 
 
C.aurantifolin 
(400mg/kg) 
66.6±4.8 
 
67.8±9.6** 
 
107.2±13.2 
 
83.5±6.4 
 
C.aurantifolin 
(200mg/kg) 
57.4±4.5 
 
71.8±5.6** 
 
68.6±4.4** 
 
67.7±6.8** 
 
Triglycerides (mg/dl) 
Control (water) 
 
108±13.6 
 
118.5±11.2 
 
135.2±19.4 
 
122.2±16.5 
 
Glibenclamide (10 
mg/kg) 
132.2±10.5 
 
140.6±10.2 
 
134.8±16.3 
 
144.4±9.4 
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C.aurantifolin 
(400mg/kg) 
11.4 ± 16.7 135.2±19.4 87±22.4** 74±20** 
C.aurantifolin 
(200mg/kg) 
131±10.5 115.2±9.7 118.4±5.3 108.5±14.9 
 
(Data are expressed in mean ± standard error of mean) 
*   =   (P<0.05), 
** = (P<0. 001) 
 
 
 
 
 
 
 
 
 
 
Table 3 
Effects of the methanolic extract of C.aurantifolin on the blood glucose, cholesterol 
and triglycerides of hyperglycaemic rats 
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Name of Group 
 
Blood Glucose (mg/dl) 
 
Time (hours) 
 0 1 2 4 
Control(water) 110±8.9  166.8±7.51 129.4±17 
 
110.4±8.5 
Glibenclamide(10mg/kg) 
 
105±5.8 
 
141.7±32.8 
 
87.38±2.89 
 
86.7±10.45* 
 
C.aurantifolin 
400mg/kg) 
100.2±2.4 
 
82.2±15** 
 
76.4±3.6** 
 
88.5±8.8** 
 
C.aurantifolin 
(200mg/kg) 
105±8.7 
 
138.2±2.1* 
 
119.1±6.7* 
 
91.9±1.6* 
Cholesterol (mg/dl) 
Control (water) 
 
75.8±6.7 
 
104.2±16.8 
 
107.2±6.4 
 
83.5±6.4 
 
Glibenclamide(10mg/kg) 
 
88±8.87 
 
87±8.2 
 
83.6±2.8* 
 
86.4±21.2 
 
C.aurantifolin 
(400mg/kg) 
72.6±5.1 
 
104.2±16.8 
 
93.2±21.6* 
 
75.8±4.6* 
 
C.aurantifolin 
(200mg/kg) 
65±3.7 
 
79.8±21.6* 
 
88.2±6.4* 
 
80±6 
 
Triglycerides (mg/dl) 
Control (water) 
 
108±13.6 
 
118.5±11.2 
 
135.2±19.4 
 
122.2±16.5 
 
Glibenclamide(10mg/kg) 
 
132.2±10.5 
 
140.6±10.2 
 
134.8±16.3 
 
144.4±9.4 
 
C.aurantifolin 
(400mg/kg) 
123.8±9.7 131.2±5.6 120.8±9.5 114.4±7.5 
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C.aurantifolin  
(200mg/kg) 
125.4±19.2 114±22.4 101.4±11.8* 99.4±16.3* 
(Data are expressed in mean± standard error of mean) 
*   =   (P<0.05), 
** = (P<0. 001) 
 
Table 4: 
Effects of the aqueous extract of C.aurantifolin on the blood glucose, cholesterol and 
triglycerides of diabetic rats: 
 
Name Of Group 
 
Blood Glucose (mg/dl) 
 
 
Time (hours) 
 0 4 8 12 
Control(water) 
 
286.2±18.2 
 
226.6±12.5 
 
202.8±56.5 
 
277±56.5 
 
Glibenclamide(10mg/kg) 
 
311.8±46.3 
 
221.2±55 
 
259.8±64.9 
 
266.6±49.4 
 
Soluble insulin (3U/kg) 273.6±18.3 286.8±6.6 226±2 222±6.6 
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 C.aurantifolin 
(400mg/kg) 
210.4±19.5 
 
249.6±20.2 
 
184.8±2.2 
 
130.8±2.2** 
 
C.aurantifolin 
(200mg/kg) 
314±44 
 
247.2±52.3 
 
180.6±14.4 
 
160.6±5** 
 
Cholesterol (mg/dl) 
Control (water.) 
 
66±10.2 61±3.7 53±5.4 56.8±5.9 
Glibenclamide(10mg/kg) 
 
98.6±18.6 112±17.4 97.4±15 56.8±4.9 
Soluble insulin (3U/kg) 
 
40.4±2.5 31.4±3* 34.2±.8 42 ±2.1 
C.aurantifolin 
(400mg/kg) 
75.8±12.7 51±4.7* 39.6±3.3* 42.8±1.1 
C.aurantifolin 
(200mg/kg) 
65.6±13.7 87.4±13 48.8±.8 47.2±.7 
Triglycerides (mg/dl) 
Control (water) 247.2±35.7 227.8±20.3 187±15.3 284±54.3 
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Glibenclamide(10mg/kg) 
 
123.2±22.5 
 
222.4±52.3 
 
247±55.9 
 
230.4±61.5 
 
Soluble insulin (3U/kg) 57.8±12.8 
 
33.2±4.8* 
 
33.6±2.5* 
 
42±6.5* 
 
C.aurantifolin 
(400mg/kg) 
122.2±14.3 55.8 ±12.8** 43.4 ± 8** 27.4 ± 0.8* 
C.aurantifolin 
(200mg/kg) 
143.2 ± 36.6 24.3 ± 37** 32.4 ±37** 44.4 ± 5.3** 
 
(Data are expressed in mean± standard error of mean) 
*   =   (P<0.05), 
** = (P<0. 001). 
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Table 5 
Effects of the methanolic extract of C.aurantifolin on the blood glucose, cholesterol 
and triglycerides of diabetic rats: 
 
Name of Group 
 
Blood Glucose (mg/dl) 
 
 
Time (hours) 
 0 4 8 12 
Control (water) 
 
286.2±18.2 
 
226.6±12.5 
 
202.8±56.5 
 
277±56.5 
 
Glibenclamide(10mg/kg) 
 
311.8±46.3 
 
221.2±55 
 
259.8±64.9 
 
266.6±49.4 
 
Soluble insulin (3U/kg) 273.6±18.3 286.8±6.6 226±2 222±6.6 
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C.aurantifolin 
(400mg/kg) 
277.8±22.7 
 
233.2±14.7 
 
179.8±16.6 
 
168.4±8.6** 
 
C.aurantifolin 
(200mg/kg) 
224.8±10 
 
223.6±6.8 
 
201±41.6 
 
171.4±29.8** 
Cholesterol (mg/dl) 
Control (water. 10ml/kg) 
 
66±10.2 61±3.7 53±5.4 56.8±5.9 
Glibenclamide(10mg/kg) 
 
98.6±18.6 112±17.4 97.4±15 56.8±4.9 
Soluble insulin (3U/kg) 
 
40.4±2.5 31.4±3* 34.2±.8 42±2.1 
C.aurantifolin 
(400mg/kg) 
58.8±5.9 33±2.7* 49.2±5.9 41±5.1 
C.aurantifolin 
(200mg/kg) 
63.4±11 48±5.4** 69±5.4 51.2±5 
Triglycerides (mg/dl) 
Control (water) 247.2±35.7 227.8±20.3 187±15.3 284±54.3 
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Glibenclamide(10mg/kg) 
 
123.2±22.5 
 
222.4±52.3 
 
247±55.9 
 
230.4±61.5 
 
Soluble insulin (3U/kg) 57.8±12.8 
 
33.2±4.8* 
 
33.6±2.5* 
 
42±6.5* 
 
C.aurantifolin 
(400mg/kg) 
210.2 ± 51.2 383.4 ±16.2 165.2 43.7* 156.8±43.7** 
C.aurantifolin 
(200mg/kg) 
179.8 ± 6.5 195 ± 57.9 165.2±61.4* 163.2±43.1** 
 
(Data are expressed in mean± standard error of mean) 
*   =   (P<0.05), 
** = (P<0. 001) 
 
Discussion: 
In accordance to the recommendations of the WHO Expert Committee
16
, on 
diabetes mellitus, it is important to investigate the hypoglycaemic action for plants 
which were traditionally used in traditional medicine 
17
  
The limited efficacy and the draw back of the currently used hypoglycemic agents 
prompted the scientists world-wide to search for more effective phytomedicenes. 
18 
 17 
More than 1200 species of plants have been used ethno-pharmacologically or 
experimentally to treat symptoms of diabetes mellitus. They represent more than 725 
genera in 183 families. The most frequently sited families are Asteraceae, Fabaceae, 
Poaceae, Laminaceae and Liliaceae 
19
. According to the taxonomy of 
20
 
C.aurantifolin belongs to the family Rutaceae. 
The biologically active components of plants with hypoglycaemic action include; 
flavonoides, alkaloids, glycosides, polysaccharides, peptidoglycans, steroids and 
terpenoides 
21.
  
In this study, phytochemical screening of C.aurantifolin revealed presence of sterols, 
alkaloids, flavonoids,tanninsm, saponin, cyanogenic glycosides and coumarins. In 
addition 
20 
 reported presence of Volatile oil, and terpenoides. 
Thus components, such as alkaloid, salicylic may be responsible for the hypoglycemic 
activity of hypoglycaemic plants 
22
. Coumarin, an active constituent of Trigonella, 
was found to have a profound hypoglycemic activity in normal and alloxan –diabetic 
rats 
23
. Thus presence of alkaloids and coumarin in C.aurantifolin, are probably 
responsible for its hypoglycaemic activity. 
 Many plants are recently studied for their hypoglycaemic effects The leaf alcohol 
extract of the plant Annona squamosa was investigated for its anti-diabetic activity in 
diabetic rats. The findings showed the significant anti diabetic potential of the extract 
in monitoring the diabetes rats
 24
.  In studying the antihyperglycemic effect of the 
ethanol extract of G. montanum leaves to Diabetic rats, the results indicatated a 
positive role of G. montanum as atherapeutic agent for Diabetes
25
  
 18 
The results of this current study, showed that the extracts of the bark of C. verum 
possess blood glucose lowering effect in both hyperglycaemic (tables 1 and 2) rats 
and in diabetic rats  ( tables 4 and 5).. Thus the folk use of this plant may be validated 
by this study. The bark of this plant seems to have a promising value for the 
development of potent phytomedicine for diabetes. 
It can be concluded that C.aurantifolin can be promising  a antidiabetic  and 
hypolipidaemic This verifies the traditional use of this plant as a hypoglycaemic 
agents. 
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